| **Supplementary Table 1: Public and patient involvement in HTA and HTA-decision making** | | | | | |
| --- | --- | --- | --- | --- | --- |
| **Country** | **Organization** | **Specifications of the decision problem** | **Information inputs into the decision-making process** | **The decision-making process** | **Public accountability and decision implementation considerations** |
| Australia | Pharmaceutical Benefits Advisory Committee | • Refer technology for consideration: anyone | • Part of sub-committee who provides advice during evaluation: patients | • Membership on advisory committee:  patient representative | No role identified |
| Australia | Medical Services Advisory Committee | • Refer technology for consideration: anyone | • Part of advisory panel who defines scope of appraisal: patients | • Membership on advisory committee:  patient representative | No role identified |
| Belgium | Drug Reimbursement Committee | No role identified | No role identified | No role identified | No role identified |
| Canada | Canadian Agency for Drugs and Technologies in Health | No role identified | • Submit information to group preparing evaluation report: patients and patient organizations | • Membership on advisory committee:  2 patient representatives (pan-Canadian Oncology Review ); public representative: 2 “public” representative Canadian Drug Expert Committee): | No role identified |
| Denmark | Danish Medicines Agency | No role identified | No role identified | No role identified | No role identified |
| France | French National Authority for Health | • Refer technology for consideration: patients and patient organizations | • Participate in defining scope of the appraisal: patients  • Participate in consultations during evaluation: patients | • Membership on advisory committee: patient representative (HAS Interdisciplinary Economic Evaluation and Public Health Committee (CEESP)) | No role identified |
| Germany | Federal Joint Committee (G-BA) | No role identified | • Participate in defining scope of the appraisal: patients  • Comment on draft protocol for evaluation: anyone  • Submit information to group preparing evaluation report: anyone | • Membership on advisory committee: patient representative | No role identified |
| Italy | Italian Medicines Agency | No role identified | No role identified | No role identified | No role identified |
| Japan | Drug Pricing Organization | No role identified | No role identified | No role identified | No role identified |
| New Zealand | Pharmaceutical Management Agency of New Zealand (PHARMAC) | • Refer technology for consideration: patients and patient organizations | • Submit information to group preparing evaluation report: anyone | No role identified | No role identified |
| Norway | Norwegian Medicines Agency | No role identified | No role identified | No role identified | No role identified |
| Scotland | Scottish Medicines Consortium | No role identified | No role identified | • Membership on advisory committee: patient representative  • Submit written testimonials: patient organizations | No role identified |
| Singapore | Singapore Ministry of Health Drug Advisory Committee | No role identified | No role identified | No role identified | No role identified |
| Spain | Ministry of Health (Directorate General of Pharmacy and Health Products) | No role identified | No role identified | No role identified | No role identified |
| Spain | National Health System Inter-territorial Council | No role identified | No role identified | No role identified | No role identified |
| Sweden | Dental and Pharmaceutical Benefits Board (TLV) | No role identified | No role identified | • Membership on advisory committee: 2 patient representative | No role identified |
| The Netherlands | Dutch Health Care Insurance Board (CVZ) | • Refer technology for consideration: patients | No role identified | No role identified | No role identified |
| United Kingdom | National Institute for Health and Clinical Excellence (NICE) | • Refer technology for consideration: patients and the general public | • Participate in defining scope of the appraisal: patient organizations  • Submit information to group preparing evaluation report: patient organizations | • Membership on advisory committee: 2 patient representative  • Submit written testimonials: patient organizations  • Comment on draft recommendations: public and patients | Appeal recommendations: patient organizations |
| United States | Centres for Medicare and Medicaid Services (CMS) | • Refer technology for consideration: patients | • Submit information to group preparing evaluation report: anyone | • Membership on advisory committee: patient representative  • Submit additional information: anyone  • Present to advisory committee: anyone | Appeal recommendations: anyone |
| Wales | All Wales Medicines Strategy Group | No information found | No information found | • Membership on advisory committee: patient representative  • Attend committee meeting: public and patients |  |